Trgovina Angion Biomedica Corp. - ANGN CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Pogoji trgovanja
| Razmik | 0.0527 | ||||||||
|
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.024068% | ||||||||
|
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.001846% | ||||||||
| Čas nočne pristojbine | 21:00 (UTC) | ||||||||
| Min. tržena količina | 1 | ||||||||
| Valuta | USD | ||||||||
| Kritje | 20% | ||||||||
| Borza | United States of America | ||||||||
| Provizija na trgovanje | 0% |
*Information provided by Capital.com
Ključni statistični podatki
| Predhodno. Zapri* | 0.4642 |
| Odpri* | 0.4688 |
| Enoletna sprememba* | -77.35% |
| Dnevni razpon* | 0.4688 - 0.4887 |
| Razpon 52 wk | 0.46-2.37 |
| Povprečni obseg (10 dni) | 22.19K |
| Povprečni obseg (3 meseci) | 1.41M |
| Tržna kapitalizacija | 15.49M |
| Razmerje P/E | -100.00K |
| Število delnic v obtoku | 30.11M |
| Prihodki | 2.30M |
| EPS | -1.29 |
| Dividenda (donosnost v %) | N/A |
| Beta | -100.00K |
| Datum naslednjega zaslužka | Mar 29, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2023 | 0.4642 | -0.0146 | -3.05% | 0.4788 | 0.4788 | 0.4642 |
| Mar 27, 2023 | 0.4799 | 0.0009 | 0.19% | 0.4790 | 0.5252 | 0.4786 |
| Mar 24, 2023 | 0.4885 | -0.0390 | -7.39% | 0.5275 | 0.5276 | 0.4884 |
| Mar 23, 2023 | 0.5307 | 0.0028 | 0.53% | 0.5279 | 0.5374 | 0.5238 |
| Mar 22, 2023 | 0.4887 | 0.0096 | 2.00% | 0.4791 | 0.4890 | 0.4791 |
| Mar 21, 2023 | 0.4789 | 0.0248 | 5.46% | 0.4541 | 0.4791 | 0.4493 |
| Mar 20, 2023 | 0.4881 | 0.0001 | 0.02% | 0.4880 | 0.4986 | 0.4739 |
| Mar 17, 2023 | 0.4887 | -0.0490 | -9.11% | 0.5377 | 0.5378 | 0.4823 |
| Mar 16, 2023 | 0.5081 | 0.0198 | 4.05% | 0.4883 | 0.5695 | 0.4883 |
| Mar 15, 2023 | 0.4930 | -0.0542 | -9.90% | 0.5472 | 0.5671 | 0.4888 |
| Mar 14, 2023 | 0.5372 | -0.0196 | -3.52% | 0.5568 | 0.5963 | 0.5372 |
| Mar 13, 2023 | 0.5377 | -0.0240 | -4.27% | 0.5617 | 0.5621 | 0.5208 |
| Mar 10, 2023 | 0.5132 | -0.0641 | -11.10% | 0.5773 | 0.5778 | 0.5054 |
| Mar 9, 2023 | 0.5568 | -0.0604 | -9.79% | 0.6172 | 0.6256 | 0.5375 |
| Mar 8, 2023 | 0.5960 | 0.0078 | 1.33% | 0.5882 | 0.6158 | 0.5882 |
| Mar 7, 2023 | 0.6060 | -0.0094 | -1.53% | 0.6154 | 0.6155 | 0.6056 |
| Mar 6, 2023 | 0.6256 | -0.0208 | -3.22% | 0.6464 | 0.6466 | 0.6079 |
| Mar 3, 2023 | 0.6156 | 0.0290 | 4.94% | 0.5866 | 0.6258 | 0.5865 |
| Mar 2, 2023 | 0.5969 | 0.0009 | 0.15% | 0.5960 | 0.6130 | 0.5960 |
| Mar 1, 2023 | 0.5883 | -0.0370 | -5.92% | 0.6253 | 0.6256 | 0.5855 |
Angion Biomedica Corp. Events
| Čas (UTC) (UTC) | Država | Dogodek |
|---|---|---|
| No events scheduled | ||
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Skupni prihodki | 2.301 | 28.312 | 2.88 | 1.487 | 4.029 |
| Prihodki | 2.301 | 28.312 | 2.88 | 1.487 | 4.029 |
| Celotni stroški prihodkov | 0 | 0.433 | 1.19 | 0.64 | 0.378 |
| Bruto dobiček | 2.301 | 27.879 | 1.69 | 0.847 | 3.651 |
| Celotni odhodki iz poslovanja | 41.922 | 66.714 | 58.153 | 40.078 | 18.371 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 14.637 | 18.488 | 17.986 | 9.601 | 5.391 |
| Raziskave in razvoj | 18.1 | 48.698 | 38.977 | 29.837 | 12.602 |
| Prihodki iz poslovanja | -39.621 | -38.402 | -55.273 | -38.591 | -14.342 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 0.719 | -2.191 | -8.249 | 0.488 | 0.401 |
| Drugo, neto | 0.095 | -13.98 | -16.527 | -2.555 | -6.084 |
| Čisti dobiček pred obdavčitvijo | -38.807 | -54.573 | -80.107 | -40.658 | -20.025 |
| Čisti dobiček po davkih | -38.807 | -54.573 | -80.107 | -40.658 | -20.025 |
| Čisti dobiček pred dodatnimi postavkami | -38.807 | -54.573 | -80.107 | -40.658 | -20.025 |
| Čisti dobiček | -38.807 | -54.573 | -80.107 | -40.658 | -20.025 |
| Total Adjustments to Net Income | 0 | -4.98 | |||
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -38.807 | -54.573 | -80.107 | -40.658 | -25.005 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -38.807 | -54.573 | -80.107 | -40.658 | -25.005 |
| Popravljen čisti dobiček | -38.807 | -54.573 | -80.107 | -40.658 | -25.005 |
| Popravljene ponderirane povprečne delnice | 30.0407 | 28.2448 | 14.7621 | 9.97635 | 9.97635 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -1.29181 | -1.93214 | -5.42652 | -4.07544 | -2.50643 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Popravljen normalizirani dobiček na enoto čistega dobička | -0.98606 | -1.96418 | -5.4226 | -4.07544 | -2.50643 |
| Gain (Loss) on Sale of Assets | 0 | -0.058 | |||
| Nenavadni odhodki (prihodki) | 9.185 | -0.905 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Skupni prihodki | 0 | 0 | 0.653 | 1.648 | 25.941 |
| Prihodki | 0 | 0 | 0.653 | 1.648 | 25.941 |
| Celotni stroški prihodkov | 0.433 | ||||
| Bruto dobiček | 25.508 | ||||
| Celotni odhodki iz poslovanja | 7.051 | 9.05 | 9.688 | 16.133 | 11.307 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 3.745 | 3.315 | 3.615 | 4.466 | 4.206 |
| Raziskave in razvoj | 0.16 | 2.938 | 6.073 | 11.667 | 6.668 |
| Prihodki iz poslovanja | -7.051 | -9.05 | -9.035 | -14.485 | 14.634 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 0.606 | 0.053 | -0.146 | 0.206 | -0.016 |
| Drugo, neto | 0.005 | 0.009 | 0.042 | 0.039 | 0.272 |
| Čisti dobiček pred obdavčitvijo | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
| Čisti dobiček po davkih | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
| Čisti dobiček pred dodatnimi postavkami | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
| Čisti dobiček | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
| Popravljen čisti dobiček | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
| Popravljene ponderirane povprečne delnice | 30.1146 | 30.1134 | 29.9739 | 29.9592 | 29.9654 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.21385 | -0.29847 | -0.3049 | -0.47531 | 0.49691 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Popravljen normalizirani dobiček na enoto čistega dobička | -0.10938 | -0.20559 | -0.3049 | -0.47531 | 0.49691 |
| Nenavadni odhodki (prihodki) | 3.146 | 2.797 | 0 | 0 | |
| Gain (Loss) on Sale of Assets | 0 |
- Letni
- Četrtletno
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 91.247 | 42.297 | 6.106 | 25.679 |
| Denarna sredstva in kratkoročne naložbe | 88.756 | 34.607 | 5.571 | 25.512 |
| Denarna sredstva in ustrezniki | 88.756 | 34.607 | 5.571 | 25.512 |
| Celotne terjatve, neto | 0.806 | 5 | 0.44 | 0.107 |
| Prepaid Expenses | 1.031 | 0.352 | 0.095 | 0.06 |
| Total Assets | 96.513 | 47.347 | 11.886 | 26.628 |
| Property/Plant/Equipment, Total - Net | 4.437 | 4.228 | 4.781 | 0.017 |
| Property/Plant/Equipment, Total - Gross | 4.954 | 4.654 | 5.109 | 0.295 |
| Accumulated Depreciation, Total | -0.517 | -0.426 | -0.328 | -0.278 |
| Long Term Investments | 0.723 | 0.822 | 0.999 | 0.932 |
| Total Current Liabilities | 11.296 | 107.449 | 26.575 | 7.355 |
| Accounts Payable | 4.71 | 5.578 | 11.239 | 0.534 |
| Accrued Expenses | 4.113 | 7.276 | 3.694 | 2.98 |
| Notes Payable/Short Term Debt | 0 | 51.43 | 5.848 | 0 |
| Other Current Liabilities, Total | 2.415 | 43.165 | 5.794 | 3.841 |
| Total Liabilities | 15.006 | 137.796 | 30.472 | 7.717 |
| Total Long Term Debt | 0.235 | 0.635 | 0 | 0 |
| Other Liabilities, Total | 3.475 | 29.712 | 3.897 | 0.362 |
| Total Equity | 81.507 | -90.449 | -18.586 | 18.911 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | |
| Common Stock | 0.3 | 0.156 | 0.095 | 0.094 |
| Additional Paid-In Capital | 296.445 | 72.136 | 63.584 | 60.138 |
| Retained Earnings (Accumulated Deficit) | -215.135 | -160.562 | -80.455 | -39.797 |
| Treasury Stock - Common | 0 | -1.846 | -1.81 | -1.524 |
| Total Liabilities & Shareholders’ Equity | 96.513 | 47.347 | 11.886 | 26.628 |
| Total Common Shares Outstanding | 29.9591 | 15.3167 | 9.97635 | 9.97635 |
| Other Current Assets, Total | 0.654 | 2.338 | ||
| Long Term Debt | 0 | 0.635 | ||
| Other Equity, Total | -0.103 | -0.333 | ||
| Other Long Term Assets, Total | 0.106 | |||
| Current Port. of LT Debt/Capital Leases | 0.058 | |||
| Capital Lease Obligations | 0.235 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 76.239 | 91.247 | 104.393 | 119.702 | 133.498 |
| Denarna sredstva in kratkoročne naložbe | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
| Denarna sredstva in ustrezniki | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
| Celotne terjatve, neto | 0 | 0.806 | 0 | 0 | 0 |
| Prepaid Expenses | 0.021 | 1.031 | 1.018 | 1.761 | 2.343 |
| Other Current Assets, Total | 3.216 | 0.654 | 0.639 | 0.628 | 0.699 |
| Total Assets | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
| Property/Plant/Equipment, Total - Net | 4.209 | 4.437 | 4.652 | 4.776 | 4.787 |
| Property/Plant/Equipment, Total - Gross | 4.758 | 4.954 | 5.137 | 5.231 | 5.219 |
| Accumulated Depreciation, Total | -0.549 | -0.517 | -0.485 | -0.455 | -0.432 |
| Long Term Investments | 0.732 | 0.723 | 0.862 | 0.843 | 0.877 |
| Other Long Term Assets, Total | 0.078 | 0.106 | 0.033 | 0.038 | 0.038 |
| Total Current Liabilities | 10.381 | 11.296 | 17.946 | 20.524 | 16.963 |
| Accounts Payable | 3.433 | 4.71 | 7.679 | 9.307 | 6.69 |
| Accrued Expenses | 6.16 | 4.113 | 6.219 | 5.522 | 4.872 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0.895 |
| Other Current Liabilities, Total | 0.728 | 2.415 | 4.048 | 5.695 | 4.506 |
| Total Liabilities | 14.056 | 15.006 | 45.426 | 48.17 | 46.757 |
| Total Long Term Debt | 0.219 | 0.235 | 0 | 0 | 0 |
| Long Term Debt | 0 | 0 | 0 | 0 | |
| Other Liabilities, Total | 3.456 | 3.475 | 27.48 | 27.646 | 29.794 |
| Total Equity | 67.202 | 81.507 | 64.514 | 77.189 | 92.443 |
| Common Stock | 0.3 | 0.3 | 0.304 | 0.303 | 0.3 |
| Additional Paid-In Capital | 296.476 | 296.445 | 298.518 | 295.636 | 292.67 |
| Retained Earnings (Accumulated Deficit) | -229.375 | -215.135 | -230.025 | -214.321 | -197.249 |
| Treasury Stock - Common | 0 | -4.21 | -4.21 | -2.991 | |
| Other Equity, Total | -0.199 | -0.103 | -0.073 | -0.219 | -0.287 |
| Total Liabilities & Shareholders’ Equity | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
| Total Common Shares Outstanding | 29.9594 | 29.9591 | 29.9331 | 29.7976 | 29.6605 |
| Current Port. of LT Debt/Capital Leases | 0.06 | 0.058 | |||
| Capital Lease Obligations | 0.219 | 0.235 |
- Letni
- Četrtletno
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Čisti prihodki/začetna postavka | -54.573 | -80.107 | -40.658 | -20.025 |
| Denarna sredstva iz poslovanja | -52.643 | -22.888 | -24.589 | -8.02 |
| Denarna sredstva iz poslovanja | 0.091 | 0.098 | 0.05 | 0.002 |
| Nedenarne postavke | 27.809 | 31.352 | 6.269 | 9.051 |
| Cash Taxes Paid | 0 | 0 | ||
| Denarna sredstva Plačane obresti | 0.007 | 0 | 0 | |
| Spremembe v obratnem kapitalu | -25.97 | 25.769 | 9.75 | 2.952 |
| Denarna sredstva pri naložbenju | -0.382 | -0.041 | -0.242 | 0 |
| Kapitalski izdatki | -0.382 | -0.041 | -0.242 | 0 |
| Denarna sredstva pri financiranju | 107.171 | 52.409 | 4.89 | 31.741 |
| Izdaja (odplačilo) delnic, neto | -0.617 | 20.813 | -0.375 | 28.596 |
| Izdaja (odplačilo) dolga, neto | 0.293 | 32.118 | 5.265 | 3.145 |
| Neto sprememba denarnih sredstev | 54.149 | 29.036 | -19.941 | 23.721 |
| Postavke denarnega toka pri financiranju | 107.495 | -0.522 | ||
| Učinki deviznih tečajev | 0.003 | -0.444 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.24 | -54.573 | -69.463 | -53.759 | -36.687 |
| Cash From Operating Activities | -15.653 | -52.643 | -38.281 | -23.082 | -12.551 |
| Cash From Operating Activities | 0.032 | 0.091 | 0.059 | 0.029 | 0.006 |
| Non-Cash Items | 0.179 | 27.809 | 25.729 | 23.505 | 21.675 |
| Changes in Working Capital | -1.624 | -25.97 | 5.394 | 7.143 | 2.455 |
| Cash From Investing Activities | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
| Capital Expenditures | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
| Cash From Financing Activities | -0.014 | 107.171 | 106.767 | 106.068 | 108.444 |
| Financing Cash Flow Items | 0 | 107.495 | -5.52 | -5.428 | -2.797 |
| Issuance (Retirement) of Stock, Net | 0 | -0.617 | 112.287 | 111.496 | 111.241 |
| Issuance (Retirement) of Debt, Net | -0.014 | 0.293 | 0 | 0 | 0 |
| Foreign Exchange Effects | -0.087 | 0.003 | -0.011 | 0.005 | -0.003 |
| Net Change in Cash | -15.754 | 54.149 | 68.129 | 82.706 | 95.849 |
| Cash Interest Paid | 0.007 |
| Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
|---|---|---|---|---|---|---|
| Satterfield (Thomas A Jr) | Individual Investor | 7.2983 | 2197825 | 623278 | 2022-12-31 | LOW |
| Vifor (International), Ltd | Corporation | 6.6269 | 1995643 | 0 | 2023-03-15 | LOW |
| EISA-ABC LLC | Corporation | 5.719 | 1722237 | 0 | 2023-03-15 | LOW |
| Goldberg (Itzhak D) | Individual Investor | 5.6193 | 1692199 | 4213 | 2023-03-15 | LOW |
| Venkatesan (Jay R) | Individual Investor | 3.9765 | 1197498 | 0 | 2023-03-15 | LOW |
| BVF Partners L.P. | Hedge Fund | 3.5574 | 1071297 | 0 | 2022-12-31 | LOW |
| Nantahala Capital Management, LLC | Hedge Fund | 3.4308 | 1033145 | -32867 | 2022-12-31 | MED |
| Ganzi (Victor F.) | Individual Investor | 3.25 | 978698 | 0 | 2023-03-15 | LOW |
| CM Management, LLC | Investment Advisor | 2.4313 | 732178 | 132178 | 2022-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1386 | 644035 | 675 | 2022-12-31 | LOW |
| Park West Asset Management LLC | Hedge Fund | 1.2311 | 370724 | 0 | 2022-12-31 | MED |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.5811 | 175000 | 0 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5593 | 168436 | -451 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.4041 | 121700 | -87277 | 2022-12-31 | HIGH |
| Omenn (Gilbert S) | Individual Investor | 0.2667 | 80326 | 0 | 2023-03-15 | LOW |
| Millennium Management LLC | Hedge Fund | 0.2502 | 75342 | -50261 | 2022-12-31 | HIGH |
| Raymond James & Associates, Inc. | Research Firm | 0.1992 | 60000 | 0 | 2022-12-31 | LOW |
| Birchview Capital, LP | Investment Advisor | 0.1806 | 54392 | 0 | 2022-12-31 | LOW |
| Ergoteles Capital | Hedge Fund | 0.1757 | 52913 | -25944 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.1696 | 51069 | 1188 | 2022-12-31 | LOW |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group500K+
Borzni posredniki
92K+
Aktivne stranke mesečno
$53M+
Mesečni obseg naložb
$30M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
Trgovalna provizija
0
- 1:1
Vzvod
1:1
- 20
- 100
- 500
- 1000
- 10000
Naložbe
Velikost posla (finančni vzvod x naložba):
Odpiranje
Zapiranje
Kratka Dolga
Angion Biomedica Corp. Company profile
O družbi Angion Biomedica Corp.
Angion Biomedica Corp. je biofarmacevtsko podjetje v pozni fazi razvoja. Osredotoča se na odkrivanje, razvoj in komercializacijo terapij z majhnimi molekulami za zdravljenje akutnih poškodb organov in fibroznih bolezni. Glavni kandidat za izdelek družbe je ANG-3777. Njegova priprava vključuje ANG-3070, rho-kinazo 2 (ROCK2) in CYP11B2. ANG-3777 je mimetik hepatocitnega rastnega faktorja (HGF), ki ga podjetje ocenjuje pri številnih akutnih poškodbah organov in povezanih indikacijah, vključno z akutno poškodbo ledvic (AKI) in poškodbami drugih organov, kot so pljuča, centralni živčni sistem (CNS) in srce. ANG-3777 ocenjuje tudi za indikacije pri akutni poškodbi pljuč (ALI), s poudarkom na sindromu akutne dihalne stiske (ARDS), ter pri akutnih poškodbah CNS. Drugi programi družbe so za zdravljenje fibroznih bolezni, ANG-3070, inhibitor tirozin kinaze (TKI), in inhibitor rho kinaze 2 (ROCK2).
| Industry: | Biotechnology & Medical Research (NEC) |
7-57 Wells Avenue
02459
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 500.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com